Phase II Trial of Sipuleucel-T and Stereotactic Ablative Body Radiation for Patients with Metastatic Castrate-Resistant Prostate Cancer

Phase II Trial of Sipuleucel-T and Stereotactic Ablative Body Radiation for Patients with Metastatic Castrate-Resistant Prostate Cancer

(1) We hypothesized that adding concurrent stereotactic ablative radiotherapy (SAbR) would increase the time to progression in patients with metastatic castrate-resistant prostate cancer (mCRPCA) treated with sipuleucel-T. (2) Patients with a history of prostate cancer (PC), radiographic evidence of...

Full description

Bibliographic Details
Main Authors: Raquibul Hannan, Michael J. Dohopolski, Laurentiu M. Pop, Samantha Mannala, Lori Watumull, Dana Mathews, Ang Gao, Aurelie Garant, Yull E. Arriaga, Isaac Bowman, Jin-Sung Chung, Jing Wang, Kiyoshi Ariizumi, Chul Ahn, Robert Timmerman, Kevin Courtney
Format: Article
Language:English
Published: MDPI AG 2022-06-01
Series:Biomedicines
Subjects:
metastatic castrate-resistant prostate cancer
stereotactic ablative radiotherapy
sipuleucel-T
immunotherapy
clinical trial
Online Access:https://www.mdpi.com/2227-9059/10/6/1419

Internet

https://www.mdpi.com/2227-9059/10/6/1419

Similar Items